**Key Points** {#FPar1}
==============

Acetazolamide, in addition to other diuretics, may improve diuresis in heart failure exacerbationsAcetazolamide may decrease dyspnea in heart failure exacerbations

Introduction {#Sec1}
============

Heart failure is a common disease associated with a high risk of hospitalization and premature death. The prevalence of heart failure is approximately 1--2% of the population in developed countries, with the risk of developing the disease rising with age \[[@CR1]\].

Fluid retention is the cause of numerous symptoms in chronic heart failure \[[@CR2]\]. The basic method for reducing fluid retention in heart failure is the administration of diuretics, but there is no evidence that this approach decreases the fatality rate. Nevertheless, guidelines from the European Society of Cardiology (ESC) recommend administration of diuretics, both in the acute and chronic phases, to obtain proper fluid balance in patients with overhydration symptoms \[[@CR3]\].

Historically, one of the first classes of diuretics used to achieve decongestion in heart failure were the carbonic anhydrase inhibitors. The currently available drug from that class, acetazolamide, acts through blockade of carbonic anhydrase in various organs. In the kidney, carbonic anhydrase is expressed mainly in proximal tubules. With its blockade, acetazolamide increases natrium and bicarbonate excretion, urine alkalosis, and blood acidosis \[[@CR4]\]. Anhydrase inhibitors were used in the treatment of volume overload in heart failure, in combination with mercurial diuretics, in the 1950s and 1960s \[[@CR5]\]. With the discovery of potent loop diuretics, the use of anhydrase inhibitors has been largely abandoned (at least in the treatment of heart failure with volume overload).

Diuretic resistance is a growing clinical problem in heart failure, and patients resistant to loop diuretics have a poor prognosis \[[@CR6]\]. Anhydrase inhibitors, which are currently used occasionally in such patients, have not been tested in the era of evidence-based medicine; however, limited animal and human data suggest a potential benefit of acetazolamide, especially in combination with loop diuretics, in the treatment of fluid overload in heart failure \[[@CR7]\]. Consequently, we conducted a pilot study to determine the putative clinical value of adding acetazolamide on top of the current diuretic therapy in patients with heart failure and signs of volume overload.

Patients and Methods {#Sec2}
====================

Study Design {#Sec3}
------------

This prospective, randomized, unblinded, single-center study was carried out in the Cardiology Department of the Centre of Postgraduate Medical Education, Warsaw, Poland, between June 2015 and February 2016. All patients provided written informed consent and the study was approved by the institutional Ethics Committee.

Population {#Sec4}
----------

Consecutive patients admitted to the cardiology ward with exacerbations of acute or chronic heart failure were screened. Eligible patients met the following criteria: x-ray-confirmed pulmonary congestion and/or the presence of signs of excess fluid (leg edema, ascites) requiring hospitalization (only patients with persistent signs of fluid overload during the initial evaluation were included); left ventricular ejection fraction (EF) \< 50%; stable diuretic therapy, defined as a stable dose of diuretics anticipated by the attending physician over the next 4 days; age ≥ 18 years; and the possibility of precise estimation of daily diuresis, determined by the investigator (i.e. patients with a Foley catheter inserted in the urinary bladder, or non-catheterized patients for whom reliable fluid balance control had been observed for the previous days).

Exclusion criteria were current acute coronary syndrome, acute pulmonary embolism, acute myocarditis, aortic dissection, stage 5 chronic kidney disease (estimated glomerular filtration rate \< 15 mL/min) or current hypotension (mean arterial pressure \< 60 mmHg).

Treatment Protocol {#Sec5}
------------------

The study design is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Patients were observed over 4 consecutive days. On day 1, patients were randomized to receive acetazolamide orally, once daily, with dose-adjustment for body weight (\< 75 kg, 250 mg; 75 − 100 kg, 375 mg; \> 100 kg, 500 mg), or no additional treatment (control group). To measure the fluid output on diuretics used before the initiation of acetazolamide and compare it with the consecutive days with the addition of a study drug, acetazolamide was only administered on days 2 and 3. Randomization was performed using a computer-generated 16-bit exact randomization procedure performed prior to commencement of the study. Treating physicians were discouraged from changing the dose of background diuretics unless considered necessary per the patient's clinical condition. Detailed data on the dose of diuretics and other medications were collected throughout the study.Fig. 1Study protocol. Acetazolamide was administered in 10 of the 20 study patients

Laboratory Measurements {#Sec6}
-----------------------

Daily natrium and chloride urine excretion were measured on all 4 study days. On days 1 and 4, serum natrium, potassium, chloride, creatinine, and glucose levels, as well as osmolality, urine osmolality, and pH were measured. Other laboratory findings, such as full blood count and N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma concentrations were collected in most patients prior to randomization.

Outcome Measurements {#Sec7}
--------------------

Clinical assessment included daily measurement of patient body mass, arterial pressure, and heart rate. Dyspnea was measured using a 10° visual analog scale and the 5° Likert-type scale.

Fluid balance was estimated on the basis of daily urine collection, carried out over 24 h, from 6:00am to 6:00am the following day. The balance of intake fluids was monitored using a questionnaire completed by patients on an ongoing basis. Additionally, the amount of intake fluids was controlled on an ongoing basis by the auxiliary staff in the ward.

Study endpoints included diuresis and fluid balance on each consecutive day, mean diuresis and fluid balance on days 2 and 3 and days 2, 3 and 4, difference in diuresis, and fluid balance on day 1 versus all other days.

Statistical Analysis {#Sec8}
--------------------

The results are presented as mean ± 1 standard deviation (SD) or median with interquartile range and 95% confidence interval. Variables were compared using Student's *t*-test or the Mann--Whitney *U* test as the groups were too small to adequately assess the eventual normality. Statistical significance was set at a probability level of \< 0.05.

The statistical packet Statistica version 10 (data analysis software system; StatSoft, Inc.) was employed for the purpose of calculations (2011).

Results {#Sec9}
=======

Study Population {#Sec10}
----------------

Twenty patients were included in the study, 10 of whom were randomized to acetazolamide and 10 to the control. The mean age of patients was 72 ± 12 years, 85% were men, and mean left ventricle EF was 33.8 ± 11.4%. Ninety-five percent of patients received furosemide (80% intravenously), 30% received oral torasemide (some patients received both furosemide and torasemide), 50% received spironolactone (30% intravenously), 10% received oral eplerenone, and 10% received oral hydrochlorothiazide. Mean intravenous furosemide dose was 101 mg/day in the acetazolamide group and 108 mg/day in the no-treatment group. With adjustment for a diuretic potency (oral furosemide twofold lower potency and oral torasemide twofold higher potency than intravenous furosemide), the mean initial dose of loop diuretics converted to intravenous furosemide was 90 mg/day in the acetazolamide group and 122 mg/day in the control group \[[@CR8]\]. The difference was not statistically significant. The mean dose of loop diuretics in the following days was similar in both groups (no statistically significant differences).

The full demographics and clinical characteristics of both study groups are presented in Table [1](#Tab1){ref-type="table"}. The mean adjusted dose of in vitro loop diuretics are presented in Table [2](#Tab2){ref-type="table"}.Table 1Baseline demographics and clinical characteristics in the control and acetazolamide-treated groupsVariableAcetazolamide \[*n* = 10\]Control \[*n* = 10\]*p* valueAge, years \[mean (± SD)\]73.0 (8.6)71.2 (14.4)0.74Men8 (80)9 (90)0.56Charlson comorbidity index (sum) \[median\]330.34Ejection fraction, % \[mean (± SD)\]37.5 (13.0)30.2 (8.7)0.16Heart failure etiology0.41 Ischemic6 (60)7 (70) Other4 (40)3 (30)Baseline NYHA class0.14 II4 (40)1 (10) III6 (60)9 (90)Coronary artery disease8 (80)7 (70)0.63Arterial hypertension8 (80)8 (80)1.0Atrial fibrillation8 (80)6 (60)0.36Chronic lung disease2 (20)2 (20)1.0Chronic kidney disease6 (60)6 (60)1.0Depression1 (10)2 (20)0.56Diabetes mellitus7 (70)5 (50)0.39Pharmacotherapy during study ACE inhibitor/ARB8 (80)8 (80)1.0 Aspirin5 (50)6 (60)0.67 Statin8 (80)5 (50)0.18 β-blocker9 (90)10 (100)0.33 Antibiotics5 (50)7 (70)0.39 Amiodarone7 (70)5 (50)0.39 OAC/LMWH7 (70)8 (80)0.063 Proton pump inhibitor7 (70)9 (90)0.29White blood cells, K/μL \[mean (± SD)\]8.95 (3.18)7.70 (1.60)0.28Hemoglobin, g/dL \[mean (± SD)\]12.19 (2.64)12.39 (1.78)0.85Troponin T, ng/L \[mean (± SD)\]43.73 (46.39) \[*n* *=* 9\]65.63 (34.40) \[*n* *=* 7\]0.31CRP, mg/dL \[mean (± SD)\]35.77 (63.52) \[*n* *=* 9\]67.51 (107.39) \[*n* *=* 9\]0.46Natrium, mEq/L \[mean (± SD)\]138.60 (3.37)137.40 (4.79)0.53Potassium, mEq/L \[mean (± SD)\]4.48 (0.53)4.97 (0.86)0.14Creatinine, μmol/L \[mean (± SD)\]137.05 (42.44)141.47 (76.93)0.88NT-proBNP, pg/mL \[mean (± SD)\]7241.29 (5417.86) \[*n* *=* 7\]8704.44 (5966.80) \[*n* *=* 9\]0.62Data are expressed as *n* (%) unless otherwise specified*ACE* angiotensin-converting enzyme, *ARB* angiotensin receptor blockers, *CRP* C-reactive protein, *LMWH* low molecular weight heparin, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *NYHA* New York Heart Association, *OAC* oral anticoagulants, *SD* standard deviation Table 2Mean ± SD  dose of loop diuretics (doses converted to intravenous furosemide dose)Day of the studyAcetazolamide (*n* *=* 10)Control (*n* *=* 10)*p* value^a^Day 190 ± 51122 ± 590.42Day 2118 ± 78130 ± 650.28Day 3103 ± 64142 ± 800.95Day 4110 ± 73152 ± 970.16Adjustment for a diuretic potency: oral furosemide has a twofold lower potency and oral torasemide a twofold higher potency than intravenous furosemide \[[@CR8]\]*SD* standard deviation^a^ *p* *\<* 0.05 for Student's *t* test considered statistically significant

Diuresis {#Sec11}
--------

Data on mean diuresis and natriuresis on each consecutive day are presented in Table [3](#Tab3){ref-type="table"}. There was no statistically significant difference between values for diuresis and natriuresis in the acetazolamide and control groups according to Student's *t* test and the Mann--Whitney *U* test. However, there was a significant increase in mean urine pH on day 4 versus day 1 in the acetazolamide group versus the control group (+ 1.07 vs. − 0.3; *p* *=* 0.02). Urine alkalization confirmed the lasting effect of acetazolamide treatment on day 4.Table 3Comparison of diuresis and natriuresis between the control and acetazolamide-treated groupsVariableAcetazolamide (*n* *=* 10)Control (*n* *=* 10)*p* value^a^Diuresis, mL \[mean (± SD)\] Day 12351.0 (806.8)2614.00 (621.3)0.42 Day 22272.0 (707.1)2802.00 (1311.8)0.28 Day 32641.0 (568.1)2617.00 (1172.3)0.95 Day 42898.0 (1160.9)2252.00 (800.5)0.16Mean diuresis, days 3 and 42769.5 (800.6)2434.50 (951.3)0.41Mean diuresis, days 2, 3 and 42603.6 (629.1)2557.00 (1065.4)0.91Natriuresis, mmol/L \[mean (± SD)\] Day 1207.9 (91.6)260.88 (149.6)0.40 Day 2212.9 (104.2)247.11 (138.7)0.55 Day 3253.1 (72.6)240.70 (131.5)0.81 Day 4258 (129.9)213.3 (112.3)0.43*SD* standard deviation^a^ *p* *\<* 0.05 for Student's *t* test considered statistically significant

Fluid Balance {#Sec12}
-------------

A comparison of fluid balance between the groups is presented in Table [4](#Tab4){ref-type="table"}. There was a trend towards a negative fluid balance in the acetazolamide group on days 3 and 4, whereas no such trend was observed in the control group. The difference on day 4 fluid balance and mean days 3 and 4 fluid balance between the acetazolamide and control groups was statistically significant, assuming a normal variable distribution (Student's *t* test), whereas the Mann--Whitney *U* test yielded no statistical significance.Table 4Comparison of fluid balance between the control and acetazolamide-treated groupsFluid balance, mL \[mean (± SD)\]Acetazolamide (*n* *=* 10)Control (*n* *=* 10)*p* value^a^Day 1−172.0 (968.7)−165.0 (858.9)0.99Day 2168.0 (1052.1)−198.0 (812.9)0.40Day 3−416.0 (486.5)152.0 (735.2)0.057Day 4−666.0 (1194.4)332.0 (704.7)0.035Fluid balance, days 3 and 4−541.0 (774.3)242.0 (655.9)0.025Fluid balance, days 2, 3 and 4−304.7 (596.0)95.3 (681.6)0.18*SD* standard deviation^a^ *p* *\<* 0.05 for Student's *t* test considered statistically significant

Dyspnea Measurement {#Sec13}
-------------------

According to both scales, dyspnea was less pronounced in the acetazolamide group (Table [5](#Tab5){ref-type="table"}). The difference escalated over each subsequent day, reaching statistical significance (Student's *t* test) on days 2, 3 and 4, but the findings were not significant when the Mann--Whitney *U* test was used.Table 5Comparison of dyspnea scores between the control and acetazolamide-treated groupsVariableAcetazolamide (*n* *=* 10)Control (*n* *=* 10)*p* value^a^Visual dyspnea scale^b^ \[mean (± SD)\] Day 126 (27)42 (13)0.12 Day 218 (18)41 (16)0.014 Day 316 (21)38 (19)0.038 Day 49 (9)35 (16)0.0006Likert \[mean (± SD)\] Day 12.278 (1.1)3 (0.8)0.13 Day 21.722 (0.7)2.833 (0.8)0.0076 Day 31.667 (0.97)2.778 (1.4)0.07 Day 41.444 (0.64)2.222 (0.83)0.041*SD* standard deviation^a^ *p* *\<* 0.05 for Student's *t* test considered statistically significant^b^Presented in mm (0--100 mm)

Discussion {#Sec14}
==========

The results of our pilot study confirm the potential effectiveness of acetazolamide in the current era of diuretic therapy in heart failure. To our knowledge, only two other human studies have been published over the past 30 years with the use of acetazolamide as a diuretic agent in heart failure \[[@CR7], [@CR9]\]. In a small prospective study in nine patients with congestive heart failure, Knauf and Mutschler showed that adding 250 mg of acetazolamide to 40 mg of furosemide produced a similar increase in the rate of diuresis as that achieved by doubling the dose of furosemide \[[@CR9]\]. Furthermore, Verbrugge et al. conducted a single-center, prospective cohort study in 54 patients with decompensated heart failure, in which a strict scheme of loop diuretic dose (intravenous bumetanide) was required per protocol. Physicians were encouraged to use combination diuretic therapy: a thiazide diuretic was recommended in patients with kidney dysfunction (estimated glomerular filtration rate \< 40 mL/min); the addition of acetazolamide was recommended when the serum urea to creatinine ratio was \> 50; and spironolactone was recommended in patients without hyperkalemia. Overall, 69% of patients received different types of combination diuretic therapy. The addition of acetazolamide was one of the few statistically significant factors that increased natriuresis (the other being higher diastolic blood pressure and lower plasma aldosterone) \[[@CR7]\].

Several mechanisms may explain the potential effectiveness of acetazolamide in combination diuretic therapy. Sodium reabsorption in proximal tubules may be increased in patients receiving chronic loop diuretic therapy or with decompensated heart failure, which in turn weakens the effectiveness of loop diuretics. This type of diuretic resistance may not be effectively treated by combination therapy with distally acting diuretics such as thiazides or mineralocorticoid receptor antagonists; however, the use of acetazolamide, a proximal tubule-acting diuretic, may be effective \[[@CR9]\]. Anhydrase inhibitors may also enhance the diuretic effect of thiazides. As shown in animal models, lower urine pH may upregulate the distal tubule sodium chloride co-transporter, despite the administration of thiazide \[[@CR9]\]. Thus, in theory and in some animal models, alkalization of the urine may augment the usefulness of thiazide diuretics \[[@CR10]\].

There are several limitations of our study. At the time the study was designed, in 2015, we were using the 2012 ESC heart failure guidelines \[[@CR11]\]. These guidelines defined normal EF as \> 50%, whereas patients with EF in the range of 35--50% were defined as in the 'grey zone'. We decided to include patients with clearly reduced EF (\< 35%) as well as those with 'grey zone' EF (35--50%). According to current guidelines, we included patients with reduced (\< 40%) and mid-range EF (40--49%) \[[@CR3]\]. The mean EF in our group was 33.8 ± 11.3%.

The small size of our study, as well as the lack of blinding, imply the need for exercising caution in interpreting our results. Many potential confounding factors influence diuresis, such as variability in ambient and body temperature and humidity, which may be difficult to avoid even in a clinical trial. The wide SDs in our results indicate a high probability of chance findings as an explanation of our results. However, the limited clinical experience mentioned above encourages generation of a hypothesis that acetazolamide may augment the diuretic response to other diuretic agents.

Conclusions {#Sec15}
===========

The results of this pilot study suggest that adding acetazolamide to other stable diuretic drugs in patients hospitalized with heart failure exacerbation may produce an additional diuretic effect and alleviation of dyspnea. These findings need to be confirmed in a larger randomized controlled study.

A comment to this article is available online at <https://doi.org/10.1007/s40261-018-0653-1>.
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